{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T12:48:06Z","timestamp":1776084486344,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"2023 Xuzhou City to promote science and technology innovation special fund key projects","award":["KC23233"],"award-info":[{"award-number":["KC23233"]}]},{"name":"2023 Xuzhou City to promote science and technology innovation special fund key projects","award":["KC23231"],"award-info":[{"award-number":["KC23231"]}]},{"name":"2024 Xuzhou Municipal Health Commission science and Technology project youth projects","award":["XWKYHT2024001"],"award-info":[{"award-number":["XWKYHT2024001"]}]},{"name":"Jiangsu Provincial Administration of Traditional Chinese Medicine Project","award":["MS2021075"],"award-info":[{"award-number":["MS2021075"]}]},{"name":"Science and Technology Project of Suzhou City of China","award":["SYW2024133"],"award-info":[{"award-number":["SYW2024133"]}]},{"name":"2023 Xuzhou Municipal Health Commission science and Technology project youth projects","award":["XWKYHT20230001"],"award-info":[{"award-number":["XWKYHT20230001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04648-3","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T18:23:27Z","timestamp":1772735007000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["IGF2BP3 promotes the muscle invasion of bladder cancer via PPAR\u03b3 dysregulation"],"prefix":"10.1007","volume":"17","author":[{"given":"Jing-yi","family":"Cao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang-yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping-An","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Tao","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Jie-Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gui-hua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Cheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sha-Sha","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quan-lan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-song","family":"Pei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi-chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"issue":"2","key":"4648_CR1","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.eururo.2023.03.029","volume":"84","author":"I Jubber","year":"2023","unstructured":"Jubber I, Ong S, Bukavina L, Black PC, Comperat E, Kamat AM, Kiemeney L, Lawrentschuk N, Lerner SP, Meeks JJ, et al. Epidemiology of bladder cancer in 2023: A systematic review of risk factors. Eur Urol. 2023;84(2):176\u201390.","journal-title":"Eur Urol"},{"issue":"8","key":"4648_CR2","first-page":"507","volume":"96","author":"KC DeGeorge","year":"2017","unstructured":"DeGeorge KC, Holt HR, Hodges SC. Bladder cancer: diagnosis and treatment. Am Fam Physician. 2017;96(8):507\u201314.","journal-title":"Am Fam Physician"},{"issue":"8","key":"4648_CR3","doi-asserted-by":"publisher","first-page":"866","DOI":"10.6004\/jnccn.2022.0041","volume":"20","author":"TW Flaig","year":"2022","unstructured":"Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander T, et al. NCCN Guidelines(R) insights: bladder Cancer, version 2.2022. J Natl Compr Canc Netw. 2022;20(8):866\u201378.","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"4648_CR4","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.ccell.2018.07.013","volume":"34","author":"C Hurst","year":"2018","unstructured":"Hurst C, Rosenberg J, Knowles M. SnapShot: bladder cancer. Cancer Cell. 2018;34(2):350\u2013350. e351.","journal-title":"Cancer Cell"},{"issue":"1","key":"4648_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","volume":"30","author":"J Hedegaard","year":"2016","unstructured":"Hedegaard J, Lamy P, Nordentoft I, Algaba F, Hoyer S, Ulhoi BP, Vang S, Reinert T, Hermann GG, Mogensen K, et al. Comprehensive transcriptional analysis of Early-Stage urothelial carcinoma. Cancer Cell. 2016;30(1):27\u201342.","journal-title":"Cancer Cell"},{"issue":"2","key":"4648_CR6","doi-asserted-by":"publisher","first-page":"e1735","DOI":"10.1002\/wrna.1735","volume":"14","author":"MA Papadimitriou","year":"2023","unstructured":"Papadimitriou MA, Panoutsopoulou K, Pilala KM, Scorilas A, Avgeris M. Epi-miRNAs: modern mediators of methylation status in human cancers. Wiley Interdiscip Rev RNA. 2023;14(2):e1735.","journal-title":"Wiley Interdiscip Rev RNA"},{"issue":"2","key":"4648_CR7","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.ymthe.2024.12.003","volume":"33","author":"KM Pilala","year":"2025","unstructured":"Pilala KM, Panoutsopoulou K, Papadimitriou MA, Soureas K, Scorilas A, Avgeris M. Exploring the methyl-verse: dynamic interplay of epigenome and m6A epitranscriptome. Mol Ther. 2025;33(2):447\u201364.","journal-title":"Mol Ther"},{"issue":"1","key":"4648_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12943-021-01447-y","volume":"21","author":"W Wan","year":"2022","unstructured":"Wan W, Ao X, Chen Q, Yu Y, Ao L, Xing W, Guo W, Wu X, Pu C, Hu X, et al. METTL3\/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N(6)-methyladenosine modification of PD-L1 mRNA in breast cancer. Mol Cancer. 2022;21(1):60.","journal-title":"Mol Cancer"},{"issue":"21","key":"4648_CR9","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1158\/0008-5472.CAN-23-0557","volume":"83","author":"J Tang","year":"2023","unstructured":"Tang J, Wang S, Weng M, Guo Q, Ren L, He Y, Cui Z, Cong M, Qin M, Yu J, et al. The IGF2BP3-COPS7B axis facilitates mRNA translation to drive colorectal cancer progression. Cancer Res. 2023;83(21):3593\u2013610.","journal-title":"Cancer Res"},{"issue":"20","key":"4648_CR10","doi-asserted-by":"publisher","first-page":"e2206744","DOI":"10.1002\/advs.202206744","volume":"10","author":"X Yang","year":"2023","unstructured":"Yang X, Bai Q, Chen W, Liang J, Wang F, Gu W, Liu L, Li Q, Chen Z, Zhou A, et al. m(6) A-Dependent modulation via IGF2BP3\/MCM5\/Notch axis promotes partial EMT and LUAD metastasis. Adv Sci (Weinh). 2023;10(20):e2206744.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"4648_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13046-021-01871-4","volume":"40","author":"X Wang","year":"2021","unstructured":"Wang X, Tian L, Li Y, Wang J, Yan B, Yang L, Li Q, Zhao R, Liu M, Wang P, et al. RBM15 facilitates laryngeal squamous cell carcinoma progression by regulating TMBIM6 stability through IGF2BP3 dependent. J Exp Clin Cancer Res. 2021;40(1):80.","journal-title":"J Exp Clin Cancer Res"},{"key":"4648_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.semcancer.2014.07.006","volume":"29","author":"M Lederer","year":"2014","unstructured":"Lederer M, Bley N, Schleifer C, Huttelmaier S. The role of the oncofetal IGF2 mRNA-binding protein 3 (IGF2BP3) in cancer. Semin Cancer Biol. 2014;29:3\u201312.","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"4648_CR13","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","volume":"62","author":"M Pawlak","year":"2015","unstructured":"Pawlak M, Lefebvre P, Staels B. Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2015;62(3):720\u201333.","journal-title":"J Hepatol"},{"issue":"1","key":"4648_CR14","doi-asserted-by":"publisher","first-page":"6160","DOI":"10.1038\/s41467-021-26421-6","volume":"12","author":"T Tate","year":"2021","unstructured":"Tate T, Xiang T, Wobker SE, Zhou M, Chen X, Kim H, Batourina E, Lin CS, Kim WY, Lu C, et al. Pparg signaling controls bladder cancer subtype and immune exclusion. Nat Commun. 2021;12(1):6160.","journal-title":"Nat Commun"},{"issue":"1","key":"4648_CR15","doi-asserted-by":"publisher","first-page":"4589","DOI":"10.1038\/s41467-019-12332-0","volume":"10","author":"C Liu","year":"2019","unstructured":"Liu C, Tate T, Batourina E, Truschel ST, Potter S, Adam M, Xiang T, Picard M, Reiley M, Schneider K, et al. Pparg promotes differentiation and regulates mitochondrial gene expression in bladder epithelial cells. Nat Commun. 2019;10(1):4589.","journal-title":"Nat Commun"},{"issue":"5","key":"4648_CR16","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0002-9440(10)63737-6","volume":"164","author":"CL Varley","year":"2004","unstructured":"Varley CL, Stahlschmidt J, Smith B, Stower M, Southgate J. Activation of peroxisome proliferator-activated receptor-gamma reverses squamous metaplasia and induces transitional differentiation in normal human urothelial cells. Am J Pathol. 2004;164(5):1789\u201398.","journal-title":"Am J Pathol"},{"issue":"4","key":"4648_CR17","doi-asserted-by":"publisher","first-page":"e1628","DOI":"10.1002\/ctm2.1628","volume":"14","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Zhou Y, Qian Y, Wei W, Lin X, Mao S, Sun J, Jin J. m(6)A-dependent upregulation of DDX21 by super-enhancer-driven IGF2BP2 and IGF2BP3 facilitates progression of acute myeloid leukaemia. Clin Transl Med. 2024;14(4):e1628.","journal-title":"Clin Transl Med"},{"issue":"11","key":"4648_CR18","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1038\/s42255-021-00488-3","volume":"3","author":"Y Jiang","year":"2021","unstructured":"Jiang Y, Peng J, Song J, He J, Jiang M, Wang J, Ma L, Wang Y, Lin M, Wu H, et al. Loss of Hilnc prevents diet-induced hepatic steatosis through binding of IGF2BP2. Nat Metab. 2021;3(11):1569\u201384.","journal-title":"Nat Metab"},{"issue":"25","key":"4648_CR19","doi-asserted-by":"publisher","first-page":"e2201452","DOI":"10.1002\/advs.202201452","volume":"9","author":"X Wang","year":"2022","unstructured":"Wang X, Xu S, Chen D. Reply to the comment on the m6A reader IGF2BP2 regulates macrophage phenotypic activation and inflammatory diseases by stabilizing TSC1 and PPARgamma. Adv Sci (Weinh). 2022;9(25):e2201452.","journal-title":"Adv Sci (Weinh)"},{"key":"4648_CR20","doi-asserted-by":"publisher","first-page":"1224516","DOI":"10.3389\/fimmu.2023.1224516","volume":"14","author":"IA Elcheva","year":"2023","unstructured":"Elcheva IA, Gowda CP, Bogush D, Gornostaeva S, Fakhardo A, Sheth N, Kokolus KM, Sharma A, Dovat S, Uzun Y, et al. IGF2BP family of RNA-binding proteins regulate innate and adaptive immune responses in cancer cells and tumor microenvironment. Front Immunol. 2023;14:1224516.","journal-title":"Front Immunol"},{"key":"4648_CR21","unstructured":"!!!. INVALID CITATION !!! [19, 20]."},{"issue":"9","key":"4648_CR22","doi-asserted-by":"publisher","first-page":"e1427","DOI":"10.1002\/ctm2.1427","volume":"13","author":"X Zhang","year":"2023","unstructured":"Zhang X, Shi L, Sun HD, Wang ZW, Xu F, Wei JF, Ding Q. IGF2BP3 mediates the mRNA degradation of NF1 to promote triple-negative breast cancer progression via an m6A-dependent manner. Clin Transl Med. 2023;13(9):e1427.","journal-title":"Clin Transl Med"},{"issue":"1","key":"4648_CR23","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12885-019-5426-6","volume":"19","author":"S Lv","year":"2019","unstructured":"Lv S, Wang W, Wang H, Zhu Y, Lei C. PPARgamma activation serves as therapeutic strategy against bladder cancer via inhibiting PI3K-Akt signaling pathway. BMC Cancer. 2019;19(1):204.","journal-title":"BMC Cancer"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04648-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04648-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04648-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T11:56:50Z","timestamp":1776081410000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04648-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4648"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04648-3","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]},"assertion":[{"value":"6 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study complied with the Declaration of Helsinki and was approved by the Xuzhou Cancer Hospital Ethics Committee (approval no. 2024-02-001-K01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the final manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"558"}}